IBI-Ag, a biotechnology portfolio company developing a new class of bioinsecticides, announced an investment round for the optimization of its first product and expansion of the product portfolio spectrum.
Investors in the round include the Bayer-Trendlines Ag Innovation Fund, a partnership between The Trendlines Group and Bayer investing in breakthrough agricultural technologies, Agriline, and the Trendlines Group. The company is also supported by grants from the Israel Innovation Authority.
IBI-Ag is developing natural, single domain antibody insecticides to increase crop production without harm to farmers, consumers, and the environment. The use of single domain antibodies as active ingredients is an innovative approach for insect control, having unique potential to serve as a novel type of highly effective agents due to their small size, stability, high-aﬃnity, high-speciﬁcity, ease of manipulation and production.
Insect damage to crops causes losses in billions of dollars annually. Wide crop distribution continues to spread the insect pest problem globally, producing an urgent need for novel and effective nature-driven solutions. The agricultural market is still largely dependent on synthetic pesticides. The market for bioinsecticides is growing rapidly offering alternative solutions to traditional pesticides enabling integrated pest management schemes